What is the story about?
What's Happening?
Myricx Bio has appointed Mohit Rawat as its new CEO, while expanding its team in the US and UK. Rawat, previously with Fusion Pharmaceuticals, brings extensive experience in biopharma leadership and innovation. The company is focused on developing novel antibody-drug conjugates (ADCs) and is preparing to enter clinical trials with its lead candidate.
Why It's Important?
The appointment of Mohit Rawat as CEO is a strategic move for Myricx Bio, as his leadership could drive the company's growth and innovation in ADC therapeutics. The expansion of the team in the US and UK positions Myricx to enhance its research capabilities and accelerate clinical development. This development is crucial for advancing cancer treatment options and addressing unmet needs in oncology.
What's Next?
Myricx Bio is expected to initiate human clinical trials for its lead ADC candidate in 2026, following its recent Series A financing. The company will continue to invest in its NMT inhibitor ADC payload platform, aiming to develop therapies that improve tolerability and overcome payload resistance. Stakeholders will be monitoring the progress of these trials and the impact on cancer treatment.
AI Generated Content
Do you find this article useful?
